This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Plunkett's Biotech & Genetics Industry Almanac 2013: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies

7) Gene Therapies and Patients' Genetic Profiles Promise a Personalized Approach to Medicine

8) Breakthrough Drugs for Cancer Treatment—Many More Will Follow

9) Few New Blockbusters: Major Drug Patents Expire While Generic Sales Growth Continues

10) Biotech and Orphan Drugs Pick Up the Slack as Blockbuster Mainstream Drugs Age

11) Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce

12) Breakthrough New Drug Delivery Systems Evolve

13) Stem Cells—Multiple Sources Stem from New Technologies

14) Government Support for Stem Cell Research Evolves

15) Stem Cells—Therapeutic Cloning Techniques Advance

16) Stem Cells—A New Era of Regenerative Medicine Takes Shape

17) Nanotechnology Converges with Biotech

18) Agricultural Biotechnology Scores Breakthroughs but Causes Controversy/Selective Breeding Offers a Compromise

19) Focus on Vaccines

20) Technology Discussion—Genomics

21) Technology Discussion—Proteomics

22) Technology Discussion—Microarrays

23) Technology Discussion—DNA Chips

24) Technology Discussion—SNPs ("Snips")

25) Technology Discussion—Combinatorial Chemistry

26) Technology Discussion—Synthetic Biology

27) Technology Discussion—Recombinant DNA

28) Technology Discussion—Polymerase Chain Reaction (PCR)

Biotech & Genetics Industry Statistics

1) Biotech Industry Overview

2) The U.S. Drug Discovery & Approval Process

3) U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2011

4) U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals:1993-2011

5) Employment in Life & Physical Science Occupations, U.S.: May 2011

6) Federal R&D & R&D Plant Funding for General Science & Basic Research, U.S.: Fiscal Years 2011-2013

7) U.S. Exports & Imports of Pharmaceutical Products: 2007-1st Quarter 2012

8) U.S. Prescription Drug Expenditures, Aggregate & Per Capita Amounts, Percent Distribution: 2006-2021

9) U.S. Prescription Drug Expenditures: 1970-2021

10) Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2011

11) Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2011-2013

12) Global Area of Biotech Crops by Country: 2011

13) Biologics & Biotechnology R&D, PhRMA Member Companies: 2010

2 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs